From $16M Net to $1B Opportunity
Progenics Picks Salix Sales of Relistor in Potential $350M Deal
If at first you don't succeed . . . Progenics Pharmaceuticals Inc. licensed rights to Relistor (methylnaltrexone bromide), its opioid-induced constipation (OIC) drug for patients with advanced disease, to Salix Pharmaceuticals Ltd. in a deal potentially worth $350 million or more.